Immutep Announces Promising New Clinical Data From Triple Combination Therapy in INSIGHT-003 Trial

Immutep, Ltd. announced new encouraging clinical data in first line NSCLC from INSIGHT-003, an investigator-initiated Phase I trial conducted by the Frankfurt Institute of Clinical Cancer Research IKF.
[Immutep, Ltd.]
Press Release

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News